siRNA Design and Synthesis
MyD88-specific siRNA sequences are designed and synthesized to target and silence MyD88 expression at the mRNA level.
Solutions
Online Inquiry
siRNA Development
Protheragen's all-inclusive siRNA construction platform supplies thorough throughout services focused on therapeutic molecules for MyD88. Using the world class oligonucleotide engineering and optimization technologies, Protheragen develops new therapeutic candidates endowed with enhanced stability, better targeted delivery and robust knockdown efficiency.
Introduction to MyD88-Targeted siRNA
MyD88-targeted small interfering RNA (siRNA) is designed to specifically silence the MyD88 gene, a critical component in immune response signaling. The siRNA, typically 21-23 nucleotides in length, is incorporated into the RNA-induced silencing complex (RISC), where it facilitates the degradation of MyD88 mRNA, thereby inhibiting its expression. Developing MyD88-targeted siRNA requires careful design of the sequence for optimal specificity, enhanced chemical stability, and efficient delivery mechanisms to ensure effective targeting and silencing of MyD88 in cells.
Fig.1 MyD88-mediated signaling pathways for pro-inflammatory response. (Saikh, K. U., 2021)Advances and Challenges in MyD88-targeted siRNA Development
Recent trends in the development of MyD88 targeted siRNA therapeutics have been geared towards improving target engagement and efficiency of cellular delivery.
Advances
Chemical modification and delivery technology development has gone a long way where MyD88-targeted siRNA therapeutics aid in cellular uptake via conjugation. Higher progression algorithms allow optimization via sequences thereby increasing specificity of targets. Furthermore, nanoformulations have vastly improved the tissue distribution and cellular uptake for targeted conjugates.
Challenges
Though there are vast advances in the field, MyD88 had several remaining challenges during treatment. Key considerations involve the ability and/shedding to maintain suppression of targets with considerate dosing guidelines as well as the ability to achieve conduction to the target deigned population. The methodical nature of MyD88 signaling networks calls for targeted evaluation of the possible compensatory responses and effects on downstream pathways.
Our Services
Protheragen contributes significantly to advancing therapeutics for MyD88-related disorders. It looks forward to promoting the establishment of MyD88-targeted siRNA therapeutics within the biotechnology space. We have extensive experience offering in-depth solutions for preclinical drug development with a particular emphasis on MyD88 drug development.
Workflow of MyD88-targeted siRNA Development
siRNA Optimization
The siRNA molecules are optimized for stability, delivery efficiency, and silencing potency, followed by bioassays to assess gene knockdown efficiency.
Preclinical Research
Conduct pharmacokinetic, pharmacodynamic, and safety studies to assess siRNA efficacy and toxicity in animal models.
Clinical Research Support
Provide support for Investigator-Initiated Trials (IITs), including trial design, regulatory preparation, and clinical testing of MyD88-targeted siRNA.
Types of MyD88-Targeted Diseases
- Autoimmune Diseases
- Inflammatory Diseases
- Transplant Rejection
- Ischemia-Reperfusion
- Allergic Diseases
- Cancers
- Neurodegenerative
- Metabolic Diseases
Protheragen is determined to provide integrated services which include the siRNA therapeutic development, disease model development, pharmacokinetics and drug safety evaluation. More importantly, we aid MyD88 related diseases and sponsor these trials allowing us to biomarker the investigation submission and develop innovative therapies.
If you are interested in our services, please don't hesitate to contact us.
Reference
- Saikh, K. U. "Myd88 and Beyond: A Perspective on Myd88-Targeted Therapeutic Approach for Modulation of Host Immunity." Immunol Res 69.2 (2021): 117-28.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.